

**Suppl. Table 1:** Clinical data of patient derived organoids

<b>Patient ID</b>	<b>Sex</b>	<b>Age at diagnosis</b>	<b>Diagnosis</b>	<b>TNM classification (UICC stage)</b>	<b>Organoid tissue of origin</b>	<b>Histology (Lauren classification)</b>	<b>Neoadjuvant chemotherapy</b>	<b>Tumor regression (Becker <i>et al.</i> ,2011)</b>
<b><i>DD107*</i></b>	<b><i>Male</i></b>	<b><i>49</i></b>	<b><i>Stomach corpus carcinoma</i></b>	<b><i>pT3, pN2, pM0 (IIa)</i></b>	<b><i>Stomach corpus</i></b>	<b><i>intestinal</i></b>	<b><i>ECF</i></b>	<b><i>3</i></b>
<b><i>DD109*</i></b>	<b><i>Male</i></b>	<b><i>56</i></b>	<b><i>Adenocarcinoma of esophagogastric junction (AEGI)</i></b>	<b><i>pT2, pN1, pM1 (IV)</i></b>	<b><i>Lung metastasis</i></b>	<b><i>diffuse</i></b>	<b><i>-</i></b>	<b><i>-</i></b>
DD143	Female	61	Adenocarcinoma of esophagogastric junction (AEGII)	pT3, pN1, pM0 (IIb)	Esophago-gastric junction	intestinal	FLOT	3
DD155	Male	56	Adenocarcinoma of esophagogastric junction (AEGI)	pT2, pN1, pM1 (IV)	Esophago-gastric junction	diffuse	-	-
DD156	Female	80	Stomach corpus carcinoma	pT3, pN0, pM0 (IIa)	Stomach corpus	mixed-type	-	-
<b><i>DD191*</i></b>	<b><i>Female</i></b>	<b><i>66</i></b>	<b><i>Adenocarcinoma of esophagogastric junction (AEGII)</i></b>	<b><i>pT3, pN1, pM0 (IIb)</i></b>	<b><i>Esophago-gastric junction</i></b>	<b><i>intestinal</i></b>	<b><i>FLOT</i></b>	<b><i>3</i></b>
DD194	Female	46	Stomach corpus carcinoma	pT4a, pN3, pM1 (IV)	Stomach corpus	diffuse	FLOT	ns

DD209	Female	60	Adenocarcinoma of esophagogastric junction (AEGII)	pT3, pN1, pM0 (IIb)	Esophago-gastric junction	diffuse	FLOT	3
DD211	Male	66	Stomach antrum carcinoma	pT3, pN1, pM0 (IIb)	Stomach antrum	intestinal	ECF	3
DD218	Female	50	Adenocarcinoma of esophagogastric junction (AEGII)	pT3, pN3, M0 (IIIb)	Esophago-gastric junction	intestinal	-	-
DD241	Male	78	Adenocarcinoma of esophagogastric junction (AEGI)	pT3, pN0, pM0 (IIa)	Esophago-gastric junction	mixed-type	ECF	1
DD256	Male	88	Adenocarcinoma of esophagogastric junction (AEGII)	pT3, pN1, pM0 (IIa)	Esophago-gastric junction	intestinal	-	-
DD257	Female	80	Stomach carcinoma	pT3, pN1, pM0 (IIb)	Stomach	mixed-type	-	-
DD260	Male	64	Stomach carcinoma	pT3, pN1, pM1 (IV)	Stomach	diffuse	Cisplatin/Capecitabine	2
DD261	Male	60	Stomach antrum carcinoma	pT3, pN3, pM1 (IV)	Stomach antrum	diffuse	FLOT	2
DD265	Male	78	Adenocarcinoma of esophagogastric junction (AEGII)	pT3, pN2, pM0 (IIIa)	Esophago-gastric junction	diffuse	-	-

DD271	Male	81	Adenocarcinoma of esophagogastric junction (AEGIII)	pT3, pN1, pM1 (IIb)	Esophago-gastric junction	intestinal	-	-
<b>DD282*</b>	<b>Female</b>	<b>81</b>	<b>Stomach antrum carcinoma</b>	<b>pT3, pN0, pM0 (IIa)</b>	<b>Stomach antrum</b>	<b>intestinal</b>	-	-
DD316	Female	58	Adenocarcinoma of esophagogastric junction (AEGIII)	pT4b, pN1, pM0 (IIb)	Esophago-gastric junction	intestinal	yes, ns	3
DD323	Female	78	Adenocarcinoma of esophagogastric junction (AEGIII)	pT4a, pN1, pM0 (IIIa)	Esophago-gastric junction	diffuse	-	-

ECF: Epirubicin/ Cisplatin/ Fluoruracil

FLOT: Fluoruracil/ Leucovorin/ Oxaliplatin/ Docetaxel

ns: not specified

\* further analyzed